News Falling flu vaccine sales in US stall CSL's Seqirus spinout CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.
News CSL will slash headcount and hive off vaccine business Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.
News UK orders 5 million bird flu jabs for pandemic preparedness The UKHSA has taken steps to prepare for a possible bird flu outbreak by placing an order with Seqirus for millions of H5 vaccine doses.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.